Skip to main content
Premium Trial:

Request an Annual Quote

Native Antigen Company Inks Distribution Deals

NEW YORK — British reagent provider The Native Antigen Company said today that it has signed distribution agreements for its products covering certain European and Asian markets.

According to Native Antigen, Biozol will distribute its line of native and recombinant viral and bacterial antigens, antibodies, and immunoassays in Germany, Switzerland, and Austria. Shanghai Bioleaf will distribute the products in China.

Native Antigen specializes in the isolation and purification of native antigens and recombinant proteins from viral and bacterial pathogens in mammalian cell expression systems. The company said its products are used by pharmaceutica companies, in vitro diagnostic assay manufacturers, and academic groups for vaccine research and serology, where correct folding and glycosylation are vital.

Specific terms of the deals were not disclosed.

"Biozol and Bioleaf are both well-established distributors who have extensive local knowledge and sales infrastructure in these overseas markets which will allow us to deliver our growing range of reagents to researchers working in academia and industry," Native Antigen Commercial Director Andy Lane said in a statement.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.